EXHIBIT 10.3


CONFIDENTIAL TREATMENT


INFORMATION MARKED BY [***] HAS BEEN
OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED PORTION HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND
EXCHANGE COMMISSION.


 





 


EXCLUSIVE
PATENT LICENSE AGREEMENT


 


THIS EXCLUSIVE PATENT
LICENSE AGREEMENT (this “Agreement”) is made by and between Regents of the University of Minnesota, a constitutional
corporation under the laws of the state of Minnesota, having a place of business at 200 Oak Street, SE, Suite 280, Minneapolis,
Minnesota 55445 (the “University”), and the Licensee identified below. The University and the Licensee agree that:


 


The Terms and Conditions
of Exclusive Patent License attached hereto as Exhibit A (the “Terms and Conditions”) are incorporated herein by reference
in their entirety. In the event of a conflict between provisions of this Agreement and the Terms and Conditions, the provisions
in this Agreement shall govern. Capitalized terms used in this Agreement without definition shall have the meanings given to them
in the Terms and Conditions. The section numbers used in the parentheses below correspond to the section numbers in the Terms and
Conditions.


 


1.           Licensee:
Arno Therapeutics, Inc., a corporation under the laws of the state of Delaware, having a place of business at 200 Route 31
North, Suite 104, Flemington, NJ 08822.


 


2.           Field(s) of Use:
All products and processes contemplated by the Licensed Patent Application.


 


3.           Territory:
Any country or territory where issued and unexpired Licensed Patents and/or Licensed Patent Applications exist.


 


4.           Effective
Date: Date of the last signature of the Agreement.


 


5.           Licensed
Technology:


 


5.1           Licensed
Patents(s): None as of the Effective Date


 







    	1



    	 



    

 




INFORMATION MARKED BY [***] HAS BEEN
OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED PORTION HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND
EXCHANGE COMMISSION.


 


5.2           Licensed
Patent Applications:


 


	Application No.	 	Country	 	Filing Date	 	Title
	61/639,407	 	US	 	27 April 2012	 	Breast Cancer Prognosis
	13/843,482	 	US	 	15 March 2013	 	Breast Cancer Prognosis
	PCT/US2013/032677	 	PCT	 	15 March 2013	 	Breast Cancer Prognosis


 


6.           Patent-Related
Expenses: The Licensee shall reimburse the University for Patent-Related Expenses incurred before and during the Term as provided
in section 6.3 of the attached Terms and Conditions. The amount of Patent-Related Expenses incurred before the Term shall not exceed
$[***].


 


7.           Sublicense
Rights: Yes


 


8.           Federal
Government Rights: Yes


 


9.           Performance
Milestones : The Licensee shall achieve the following milestones:


 


[***] 


 


10.         Commercialization
Reports: Within 30 days of 31 December of each year, Licensee shall deliver written commercialization reports to the University
as provided in section 5.4 of the Terms and Conditions.


 


11.         Payments:
All amounts are non-refundable, and payable as defined below or as specified in the University’s invoice.


 


11.1         Upfront
Payment: [***] dollars ($[***]), payable within five (5) business days after the Effective Date.


 


11.2         Annual
Maintenance Fee: [***] dollars ($[***]), payable on each anniversary of the Effective Date.


 


11.3         Document
Fee: NONE.


 


11.4         Running
Royalties and Annual Minimums.





 




    	2



    	 



    

 




INFORMATION MARKED BY [***] HAS BEEN
OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED PORTION HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND
EXCHANGE COMMISSION.


 




11.4.1 Subject
to subsection 11.4.2, the Licensee shall pay the University a royalty of [***] percent ([***]%) of the Net Sales Amount on sales
of Licensed Product by Licensee and its Sublicenses, determined and payable as provided in section 6.4 of the Terms and Conditions.
Licensee’s obligation to pay royalties on sales of Licensed Products shall terminate on a Licensed Product-by-Licensed Product
and country-by-country basis upon the first date when there is no longer a valid claim under a Licensed Patent and/or Licensed
Patent Application covering such Licensed Product in the country in which such Licensed Product is either made or sold.


 


11.4.2 The
annual minimum amount of Royalties owed by the Licensee under subsection 11.4.1 shall be [***] dollars ($[***]). This annual minimum
amount shall only be due once a Licensed Product is approved by the FDA and marketed.


 


11.5         Sublicense
Fees. Within thirty (30) days after the last day of each calendar quarter, during the term of this Agreement and the Post-Termination
Period, the Licensee shall pay to the University [***] percent ([***]%) of all Sublicense Revenues as earned by the Licensee during
such quarter.


 


11.6         Other
Payments: When commercial sales of a Licensed Product reach cumulative sales greater than [***] dollars ($[***]), Licensee shall
pay the University a one-time payment of [***] ($[***]) dollars, in addition to any royalties due.


 


11.7         Equity:
NONE.


 


11.8         Transfer
Payment: [***] dollars ($[***]), payable as provided in section 12.5 of the Terms and Conditions, if at the time of the transfer
or change of control Licensee has an ongoing or completed clinical study intended for the registration of onapristone in patients
with breast cancer, that includes or is aided by a companion diagnostic based on the progesterone receptor gene signature technology.


 


11.9         Administrative
Handling Fee: [***] dollars ($[***]), payable as provided in subsection 8.1.1 of the Terms and Conditions.


 


11.10       Interest
Rate: [***] percent ([***]%) per annum.


 


11.11       Other:
NONE.


 


12.         Licensee’s
Address for Notice (§12.13). Notices will be sent to the Licensee at:


 


Arno Therapeutics Inc.


Attn: Dr. Alex Zukiwski, Chief Medical
Officer


200 Route 31 North


Suite 104


Flemington, NJ 08822





 




    	3



    	 



    

 




INFORMATION MARKED BY [***] HAS BEEN
OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED PORTION HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND
EXCHANGE COMMISSION.




 


Email: az@arnothera.com


 


13.         Licensee’s
Contact Person for Patent Prosecution Consultation (§4.2.1). The University will, as set forth in this Agreement,
communicate with the contact person named below with respect to patent prosecution and maintenance: (Upon ten (10) days prior written
notice to the University, the Licensee may change the person designated below.)


 


Arno Therapeutics Inc.


Attn: Dr. Alex Zukiwski, Chief Medical
Officer


200 Route 31 North


Suite 104


Flemington, NJ 08822


Email: az@arnothera.com


 


IN WITNESS WHEREOF,
the parties hereto have caused their duly authorized representatives to execute this Agreement.


 


	Regents of the University of Minnesota	 	Arno Therapeutics, Inc.
	 	 	 	 	 
	By:	/s/ Richard Huebsch	 	By:	/s/ Glenn R. Mattes
	 	Richard Huebsch	 	 	Glenn. R. Mattes
	 	Associate Director	 	 	Chief Executive Officer
	 	Office for Technology Commercialization	 	 	 
	 	 	 	 	 
	Date: 	February 21, 2014	 	Date:	February 26, 2014


 





 




    	4



    	 



    

 


INFORMATION MARKED BY [***] HAS BEEN
OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED PORTION HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND
EXCHANGE COMMISSION.




 





 


EXHIBIT
A


Terms
and Conditions


Exclusive
Patent License Agreement


 


These terms and conditions
to the Exclusive Patent License Agreement (“Terms and Conditions”) govern the grant of license by Regents of the University
of Minnesota (“University”) to the Licensee identified in the Exclusive Patent License Agreement (the “EPLA”).
These Terms and Conditions are incorporated by reference into the EPLA. All section references in these Terms and Conditions refer
to provisions in these Terms and Conditions unless explicitly stated otherwise.


 


1.           Definitions.
For purposes of interpreting this Agreement, the following terms have the following meanings:


 


1.1           “Affiliate”
means an entity that controls the Licensee or the Sublicensee, as the case may be, is controlled by the Licensee or Sublicensee,
or along with the Licensee or Sublicensee, is under the common control of a Third Party. An entity shall be deemed to have control
of the controlled entity if it owns, directly or indirectly, fifty percent (50%) or more of the outstanding voting securities of
the controlled entity.


 


1.2           “Commercial
Sale” means a bona fide sale, use, lease, transfer or other disposition for value of a Licensed Product by the Licensee or
a Sublicensee to a Third Party that is not an Affiliate of the Licensee.


 


1.3           “EMA”
means the European Medicines Agency.


 


1.4           “FDA”
means the United States Food and Drug Administration.


 


1.5           “Field
of Use” means the field(s) of use described in section 2 of the EPLA.


 


1.6           “Inventor(s)”
shall mean the persons named as inventors in the Licensed Patents or Licensed Patent Applications.


 


1.7           “Licensed
Patent” means the patent(s) described in section 5.1 of the EPLA, together with any issued and unexpired patent(s) issued
during the Term that arose out of a Licensed Patent Application. “Licensed Patent” also means any reissues or reexaminations
of a Licensed Patent that contain one or more claims directed to Licensed Technology.


 




    	A-1



    	 



    

 


INFORMATION MARKED BY [***] HAS BEEN
OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED PORTION HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND
EXCHANGE COMMISSION.




 


1.8           “Licensed
Patent Application” means the pending patent application(s) described in section 5.2 of the EPLA. “Licensed Patent
Application” also means any related applications including, continuations, continuations-in-part, and divisionals of a Licensed
Patent Application.


 


1.9           “Licensed
Product” means any product or good in the Field of Use that is made by, made for, sold, transferred, or otherwise disposed
of by the Licensee or its Sublicensees during the Term and the Post-termination Period and that, but for the granting of the rights
set forth in this Agreement, would (i) infringe (including under the doctrine of equivalents) one or more issued and valid claims
in a Licensed Patent; or (ii) is covered by one or more claims in a Licensed Patent Application, or any product or good that is
made using a process or method that, but for the granting of rights set forth in this Agreement, would (i) infringe (including
under the doctrine of equivalents) one or more issued and valid claims in a Licensed Patent; or (ii) is covered by one or more
claims in a Licensed Patent Application. For purposes of this Agreement, claims in a Licensed Patent Application are to be treated
as if they were allowed as proposed until such time as such claim is disallowed, withdrawn or otherwise no longer the subject of
a Licensed Patent Application. “Licensed Product” also means any service provided by or for the Licensee or its sublicensees,
but for the granting of the rights set forth in this Agreement, would (i) infringe (including under the doctrine of equivalents)
one or more claims in a Licensed Patent; or (ii) is covered by one or more claims in a Licensed Patent Application.


 


1.10         “Licensed
Technology” means, collectively, the inventions claimed in each Licensed Patent and each Licensed Patent Application.


 


1.11         “Licensee”
means the entity identified in section 1 of the EPLA.


 


1.12         “Net
Sales Amount” means the gross amount invoiced for a Commercial Sale of a Licensed Product minus (i) all trade, quantity,
and cash discounts actually allowed, (ii) all credits and allowances actually granted due to rejections, returns, billing errors,
and retroactive price reductions, (iii) applicable tariffs and duties, (iv) applicable excise, sale and use taxes, and (v) transportation
and transportation insurance, packaging (for shipping purposes only) and freight charges. Notwithstanding any provision of this
Agreement to the contrary, if the Licensee or a Sublicensee sells, leases, transfers or otherwise disposes of a Licensed Product
to an Affiliate, the “Net Sales Amount” for such transaction shall equal (a) the amount the Licensee or the Sublicensee,
as the case may be, generally charges non-Affiliate third parties a similar transaction for the Licensed Product or (b) if the
Licensee or the Sublicensee does not offer to sell the Licensed Product to the public, the amount charged by the Licensee or the
Sublicensee for a product of similar kind, quality, and quantity. In the event that a Licensed Product is sold in combination with
another product, Net Sales Amount, for purposes of calculating royalty payments on the combination product, shall be calculated
by multiplying the Net Sales Amount on sale of that combination product by the fraction A/B, where A is the gross selling price
of the Licensed Product sold separately and B is the gross selling price of the combination product; provided, however,
that in no event shall the Net Sales Amount attributed to the Licensed Product in such combination product be less than the Net
Sales Amount of such Licensed Product sold separately. In the event that no such separate sales are made by Licensee (or a Sublicensee),
Net Sales Amount for royalty determination shall be calculated by multiplying Net Sales Amount of the combination by the fraction
C/(C+D) where C is the fully allocated cost of the Licensed Product and D is the fully allocated cost of other components, such
standard costs being determined using Licensee’s (or Sublicensee’s, as applicable,) standard accounting procedures.


 




    	A-2



    	 



    

 


INFORMATION MARKED BY [***] HAS BEEN
OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED PORTION HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND
EXCHANGE COMMISSION.




 


1.13         “Patent-Related
Expenses” means costs and expenses (including out-of-pocket attorneys’ fees, patent agent fees and governmental filing
fees) that the University incurred in prosecuting and maintaining the Licensed Technology during the period preceding the Effective
Date.


 


1.14         “Performance
Milestone” means an act or event specified in section 5.1 and described in section 9 of the EPLA.


 


1.15         “Post-termination
Period” means the one hundred eighty (180) day period commencing on the date of termination or expiration of the Term.


 


1.16         “Sublicensee”
means a Third Party not Affiliated with Licensee to which the Licensee grants, a sublicense of the rights granted to it hereunder.


 


1.17         “Sublicense
Revenues” means all revenue, in whatever form but excluding Sublicense Royalties, earned by the Licensee in consideration
of its granting a Third Party a sublicense to any of its rights under this Agreement, including, without limitation, receipt of
annual milestone attainment, sublicense issuance, maintenance or up-front payments, or technology access fee; and issuance of securities
or real, personal or intangible property.


 


1.18         “Sublicense
Royalties” means a royalty paid to the Licensee that is earned on Commercial Sales of Licensed Products by Sublicensees and
that is determined as percentage of the Net Sales Amount of such Commercial Sale or as a per unit amount by the Sublicensee.


 


1.19         “Termination
Fee” means the sum of [***] dollars ($[***]).


 


1.20         “Territory”
means the geographical area described in section 3 of the EPLA.


 


1.21         “Third
Party” means any party other than the University or Licensee.


 


1.22         “Transfer
Payment” means the payment to be made by the Licensee to the University specified in section 12.5 and described in section
11 of the EPLA.


 




    	A-3



    	 



    

 


INFORMATION MARKED BY [***] HAS BEEN
OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED PORTION HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND
EXCHANGE COMMISSION.




 


2.           Term.
The term of this Agreement commences on the Effective Date as defined in section 4 of the EPLA and, unless terminated earlier
as provided in section 8, expires on the date on which both no Licensed Patent is active in the Territory and no Licensed Patent
Application is pending in the Territory (the “Term”).


 


3.           Grant
of License.


 


3.1           Licensee’s
Rights.


 


3.1.1           Subject
to the terms and conditions of this Agreement, the University hereby grants to the Licensee, and the Licensee hereby accepts, an
exclusive license to practice under the Licensed Patents and Licensed Patent Applications, to make (including to have made on its
behalf), use, offer to sell or sell (including to have sold on its behalf), offer to lease or lease (including to have leased on
its behalf), import, or otherwise offer to dispose or dispose of Licensed Products in the Territory. No provision of this Agreement
is to be construed to grant the Licensee, by implication, estoppel or otherwise, any rights (other than the rights expressly granted
it in this Agreement) to the Licensed Technology, a Licensed Patent or Licensed Patent Application, or to any other University-owned
technology, patent applications, or patents.


 


3.1.2           The
Licensee shall not sublicense its rights under this Agreement, unless otherwise provided in section 7 of the EPLA. If so provided,
the Licensee may sublicense it rights under this Agreement only as follows: the Licensee shall deliver to the University a true,
correct, and complete copy of the sublicense agreement or other agreement under which the Licensee purports or intends to grant
such sublicense rights within ten (10) days after the execution of such agreement. The Licensee shall not enter into such agreement
if the terms of the agreement are inconsistent in any respect with the terms of this Agreement, including without limitation, sections
5.2 - 5.6, 6.5, 8.3, 9.5, 10.4, and 11.3. Any sublicense made in violation of this subsection is void and constitutes an event
of default under subsection 8.1.1.


 


3.2           The
United States Government’s Rights. If the University indicated in section 8 of the EPLA that the United States federal government
funded the development, in whole or in part, of the Licensed Technology, then (i) the federal government may have certain rights
in and to the Licensed Technology as those rights are described in Chapter 18, Title 35 of the United States Code and accompanying
regulations, including Part 401, Chapter 37 of the Code of Federal Regulations, and (ii) the parties’ rights and obligations
with respect to the Licensed Technology, including the grant of license set forth in subsection 3.1.1, are subject to the applicable
terms of these laws and regulations.


 




    	A-4



    	 



    

 


INFORMATION MARKED BY [***] HAS BEEN
OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED PORTION HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND
EXCHANGE COMMISSION.




 


3.3           The
University’s Rights. The University retains an irrevocable, world-wide, royalty-free, non-exclusive right to use the Licensed
Technology for teaching, research and educational purposes. The University shall have the right to sublicense its rights under
this section to one or more non-profit academic or research institutions. The University shall have the specific right to use the
Licensed Technology in research projects sponsored by for-profit entities. However, notwithstanding anything to the contrary contained
in this Agreement, in no event shall the University grant to any commercial or for-profit entity any right to offer to sell, sell,
make, have made, or use the Licensed Technology. Furthermore, in no event shall the Inventors use the Licensed Technology in research
projects sponsored by for-profit entities for a period of three (3) years from the Effective Date of this Agreement if (i) the
research project relates to the further development or improvement of the Licensed Technology, and (ii) Licensee has agreed to
provide complete funding for the research project. The foregoing sentence applies only so long as such Investors are employees
of the University during such 3-year period. The University shall have the right to sublicense its rights under this section to
one or more non-profit academic or research upon request by such institutions after notifying Licensee of University's intent to
grant such sublicense.


 


4.           Applications
and Patents.


 


4.1           Pre-EPLA
Patent Filings. The Licensee acknowledges that it has reviewed each Licensed Patent and each Licensed Patent Application and that
it will not dispute the inventorship, validity, or enforceability of any of the claims made in a Licensed Patent or a Licensed
Patent Application. The Licensee further represents that as of the Effective Date, it has not and does not manufacture, have manufactured,
offer to sell, sell, offer to lease, lease, or import (a) any product or good that infringes (including under the doctrine
of equivalents) a claim in any Licensed Patent or Licensed Patent Application, or (b) any product or good that is made using a
process or machine that infringes (including under the doctrine of equivalents) a claim in a Licensed Patent or Licensed Patent
Application.


 


4.2           Patent
Application Filings during the Term of this Agreement.


 


4.2.1           The
University and the Licensee shall consult with each other to determine in which countries patent application(s) will be filed and
prosecuted with respect to the Licensed Technology; provided, however, that the University shall file and prosecute
such patent applications in any country so determined by the Licensee. The University shall retain counsel of its choice to file
and prosecute such patent applications. The University shall inform the Licensee of the status of the prosecution of the patent
application, including delivering to the Licensee pertinent notices, written and oral communications with governmental officials,
and documents, and shall consult with the Licensee on the prosecution of the patent application(s). The parties shall cooperate
with each other in the filing and prosecution of all patent applications with respect to the Licensed Technology. In furtherance
of the foregoing, the Licensee shall notify the University, in writing, of the individual whom the Licensee has designated to consult
and cooperate as provided in this subsection and is identified in section 13 of the EPLA. The Contact Person shall respond to the
University’s request for consultation and cooperation on a pending matter within five business days or sooner as may be required
under the circumstances. If the Contact Person fails to respond in such time period, the University, exercising its own judgment
and discretion, may respond to the matter as it deems appropriate. Except as provided in subsection 4.2.2, the Licensee shall reimburse
the University for all Patent-Related Expenses as provided in section 6.3 and in section 6 of the EPLA.


 



    	A-5



    	 



    




 


4.2.2           The
grant of license in section 3.1 shall extend to and include any patent applications and issued patents filed and prosecuted in
accordance with subsection 4.2.1. However, the grant of license in section 3.1 and the definition of Territory in section 1.16
shall not extend to or include any country in which Licensee elects, in writing to the University, not to pay or reimburse the
payment of the cost, in whole or in part, to seek or maintain intellectual property protection.


 


4.2.3           Subject
to subsection 4.2.2, no provision of this Agreement limits, conditions, or otherwise affects the University’s right to prosecute
a patent application with respect to the Licensed Technology in any country. The University retains the sole and exclusive right
to file or otherwise prosecute a patent application with respect to the Licensed Technology; provided, however, that
the University shall file and prosecute a patent application with respect to the Licensed Technology in any country that the Licensee
determines in accordance with subsection 4.2.1. In no event shall the Licensee file a patent application with respect to the Licensed
Technology. The Licensee shall cooperate with the University in the filing and prosecution of all patent applications with respect
to the Licensed Technology.


 


4.3           Rights
in the Licensed Patents and Licensed Patent Applications. No provision of this Agreement grants the Licensee any rights, titles,
or interests (except for the grant of license in subsection 3.1.1) in the Licensed Patents or Licensed Patent Applications, notwithstanding
the Licensee’s payment of all or any portion of the patent prosecution, maintenance, and related costs.


 


5.           Commercialization.


 


5.1           Commercialization
and Performance Milestones. The Licensee shall use its commercially reasonable efforts, consistent with sound and reasonable business
practices and judgment, to commercialize the Licensed Technology and to manufacture and offer to sell and sell Licensed Products
as soon as practicable and to maximize sales thereof. The Licensee shall perform, or shall cause to happen or be performed, as
the case may be, all the performance milestones described in section 9 of the EPLA.


 




    	A-6



    	 



    

 


INFORMATION MARKED BY [***] HAS BEEN
OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED PORTION HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND
EXCHANGE COMMISSION.




 


5.2           Covenants
Regarding the Manufacture of Licensed Products. The Licensee hereby covenants and agrees that the manufacture, use, sale, or transfer
of Licensed Products shall comply with all applicable federal and state laws, including all federal export laws and regulations.
The Licensee hereby further covenants and agrees that, pursuant to and to the extent required by 35 United States Code Section
204, it shall, and it shall cause each Sublicensee, to substantially manufacture in the United States of America all products embodying
or produced through the use of an invention that is subject to the rights of the federal government of the United States of America.


 


5.3           Export
and Regulatory Compliance. The Licensee understands that the Arms Export Control Act (AECA), including its implementing
International Traffic In Arms Regulations (ITAR,) and the Export Administration Act (EAA), including its Export Administration
Regulations (EAR), are some (but not all) of the laws and regulations that comprise the U.S. export laws and regulations. Licensee
further understands that the U.S. export laws and regulations include (but are not limited to): (i) ITAR and EAR product/service/data-specific
requirements; (ii) ITAR and EAR ultimate destination-specific requirements; (iii) ITAR and EAR end user-specific requirements;
(iv) Foreign Corrupt Practices Act; and (v) antiboycott laws and regulations. The Licensee shall comply with all then-current applicable
export laws and regulations of the U.S. Government (and other applicable U.S. laws and regulations) pertaining to the Licensed
Products (including any associated products, items, articles, computer software, media, services, technical data, and other information).
The Licensee certifies that it shall not, directly or indirectly, export (including any deemed export), nor re-export (including
any deemed re-export) the Licensed Products (including any associated products, items, articles, computer software, media, services,
technical data, and other information) in violation of U.S. export laws and regulations or other applicable U.S. laws and regulations.
The Licensee shall include an appropriate provision in its agreements with its authorized Sublicensees to assure that these parties
comply with all then-current applicable U.S. export laws and regulations and other applicable U.S. laws and regulations.


 


5.4           Commercialization
Reports. Throughout the Term and during the Post-termination Period, and within thirty (30) days of the date specified in the schedule
set forth in section 10 of the EPLA, the Licensee shall deliver to the University written reports of the Licensee’s and the
Sublicensees’ efforts and plans to commercialize the Licensed Technology and to manufacture, offer to sell, or sell Licensed
Products.


 




    	A-7



    	 



    

 


INFORMATION MARKED BY [***] HAS BEEN
OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED PORTION HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND
EXCHANGE COMMISSION.




 


5.5           Use
of the University’s Name and Trademarks or the Names of University Faculty, Staff, or Students. No provision of this Agreement
grants the Licensee or Sublicensee any right or license to use the name, logo, or any marks owned by or associated with the University
or the names, or identities of any member of the faculty, staff, or student body of the University. The Licensee shall not use
and shall not permit a Sublicensee to use any such logos, marks, names, or identities without the University’s and, as the
case may be, such member’s prior written approval.


 


5.6           Governmental
Markings.


 


5.6.1           The
Licensee shall mark all Licensed Products, where feasible, with patent notice appropriate under Title 35, United States Code.


 


5.6.2           The
Licensee is responsible for obtaining all necessary governmental approvals for the development, production, distribution, sale,
and use of any Licensed Product, at the Licensee’s expense, including, without limitation, any safety studies. The Licensee
is responsible for including with the Licensed Product any warning labels, packaging and instructions as to the use and the quality
control for any Licensed Product.


 


5.6.3           The
Licensee agrees to register this Agreement with any foreign governmental agency that requires such registration, and the Licensee
shall pay all costs and legal fees in connection with such registration. The Licensee shall comply with all foreign laws affecting
this Agreement or the sale of Licensed Products.


 


6.           Payments,
Reimbursements, Reports, and Records.


 


6.1           Payments.
The Licensee shall pay all amounts due under this Agreement by wire transfer to the University, or any other mutually agreed-upon
method of payment.


 


6.2           Interest.
All amounts due under this Agreement shall bear interest as provided in section 11 of the EPLA on the entire unpaid balance computed
from the due date until the amount is paid.


 


6.3           Reimbursement
of Patent-Related Expenses. The Licensee shall pay invoices for Patent-Related Expenses under this Agreement within thirty (30)
days of its receipt of the University’s invoice. With respect to each invoice, the University shall specify the date on which
the Patent-Related Expense was incurred and the purpose of the expense (including, as applicable, a summary of patent attorney
services giving rise to the expense); provided, however, the University is not required to disclose to the Licensee any information
that is protected by the University’s attorney-client privilege. Patent-Related Expenses incurred as of the Effective Date
are set forth in section 6 of the EPLA. The University reserves the right to require that Licensee provide and maintain a reasonable
advance deposit with the University or some other form of security to ensure payment of Patent-Related Expenses.


 




    	A-8



    	 



    

 


INFORMATION MARKED BY [***] HAS BEEN
OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED PORTION HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND
EXCHANGE COMMISSION.




 


6.4           Royalty
Payments/Sales Reports. Following the first Commercial Sale, within sixty (60) days after the last day of the second and fourth
calendar quarters during the Term and the Post-termination Period, the Licensee shall deliver to the University a written sales
report in the form acceptable to the University, recounting the number and Net Sales Amount (expressed in U. S. dollars) of all
sales, leases, or other dispositions of Licensed Products, whether made by the Licensee or a Sublicensee, during such semi-annual
period. The Licensee shall deliver such written report to the University even if the Licensee is not required hereunder to pay
to the University a payment for sales, leases, or other dispositions of Licensed Products during the semi-annual period. The Licensee
shall deliver along with such sales reports its payment for royalties owed on all Commercial Sales of Licensed Products by the
Licensee and the Sublicensees during such semi-annual period.


 


6.5           Records
Retention and Audit Rights.


 


6.5.1           Throughout
the Term and the Post-termination Period and for five (5) years thereafter, the Licensee, at its expense, shall keep and
maintain and shall cause each Sublicensee and each non-affiliated Third Party that manufactures, sells, leases, or otherwise disposes
of Licensed Products on behalf of the Licensee to keep and maintain complete and accurate records of all sales, leases, and other
dispositions of Licensed Products during the Term and the Post-termination Period and all other records related to this Agreement.


 


6.5.2           In
connection with an audit, the Licensee, upon written request, shall deliver to the University and its representatives true, correct
and complete copies of all documents and materials (including electronic records) reasonably relevant to the Licensee’s and
Sublicensees’ performance of this Agreement, including, without limitation, all sublicenses granted.


 




    	A-9



    	 



    

 


INFORMATION MARKED BY [***] HAS BEEN
OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED PORTION HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND
EXCHANGE COMMISSION.




 


6.5.3           To
determine the Licensee’s compliance with the terms of this Agreement, the University, at its expense (except as set forth
in this subsection), may inspect and audit the Licensee’s records referred to in subsection 6.5.1 at the Licensee’s
address as set forth in this Agreement or such other location(s) as the parties mutually agree during the Licensee’s normal
business hours. The University’s right to conduct inspections and audits pursuant to this Section 6.5.3 shall be limited
to once in each calendar year. The Licensee shall cooperate in the audit, including providing at no cost, commodious space in the
Licensee’s place of business for the auditor. The Licensee shall reimburse the University for all its out-of-pocket expenses
to inspect and audit such records if the University, in accordance with the results of such inspection and audit, determines that
the Licensee has underpaid amounts owed to the University by at least [***] percent ([***]%) in a reporting period. The Licensee
shall cause each Sublicensee and each non-affiliated Third Party that manufactures, sells, leases, or otherwise disposes of Licensed
Products on behalf of the Licensee to grant the University a right to inspect and audit the Sublicensee’s or Third Party’s
records substantially similar to the rights granted the University in this subsection. In connection with, and before the commencement
of, an audit, if the Licensee requests in writing to the University, then prior to conducting such audit, the Licensee, the University
and the auditor must enter into an agreement prohibiting the auditor and the University from disclosing the Licensee’s nonpublic,
proprietary information to any Third Party without the Licensee’s prior written consent; provided, however, that consistent
with generally accepted auditing standards and the auditor’s professional judgment, the auditor may disclose such information
to the University and its agents, counsel, or consultants. The Licensee acknowledges that such an agreement is adequate to protect
its legitimate interests, and the parties agree that there shall be no additional nondisclosure agreement demanded as a condition
to the commencement of an audit and the University’s exercising its rights under this subsection.


 


6.6           Currency
and Checks. All computations and payments made under this Agreement shall be in United States dollars. To determine the dollar
value of transactions conducted in non-United States dollar currencies, the parties shall use the exchange rate for the currency
into dollars as reported in the Wall Street Journal as the New York foreign exchange mid-range rate on the last business
day of the month in which the transaction occurred.


 


7.           Infringement.


 


7.1           If
a party learns of substantial, credible evidence that a Third Party is making, using, or selling a product in the Field of Use
in the Territory that infringes a Licensed Patent, such party shall promptly notify the other party in writing of the possible
infringement and in such notice describe in detail the information suggesting infringement of the Licensed Patent. Prior to commencing
any action to enforce a Licensed Patent, the parties shall enter into good faith negotiations on the desirability of bringing suit,
the parties to the action, the selection of counsel, and such other matters as the parties may agree to discuss. No provision of
this Agreement limits, conditions, or otherwise affects a party’s statutory and common-law rights to commence an action to
enforce a Licensed Patent. In any such action, the parties agree to cooperate fully with each other and will use reasonable efforts
to permit access to relevant personnel, records, papers, information, samples and specimens during regular business hours. Any
amounts recovered (less amounts actually paid for reasonable attorney’s fees and legal expenses) by Licensee in any such
action or settlement that constitute compensation for lost profits or sales will be considered subject to the royalty rate in subsection
11.4.1 of the EPLA. All other amounts recovered (less amounts actually paid for reasonable attorney’s fees and legal expenses)
by Licensee in such action or settlement shall be considered subject to the rate for Sublicense Revenues in section 11.5 of the
EPLA.


 




    	A-10



    	 



    

 


INFORMATION MARKED BY [***] HAS BEEN
OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED PORTION HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND
EXCHANGE COMMISSION.




 


7.2.          If
any suit, action or proceeding is brought or commenced against the Licensee alleging the infringement of a patent or other intellectual
property right owned by a Third Party by reason of the manufacture, use or sale of Licensed Products, the Licensee shall give the
University prompt notice thereof. If the validity of a Licensed Patent is questioned in such suit, action or proceeding, the Licensee
shall have no right to make any settlement or compromise which affects the scope, validity, enforceability or otherwise the Licensed
Patent without the University’s prior written approval.


 


8.           Termination.


 


8.1.          By
the University.


 


8.1.1           If
the Licensee breaches or fails to perform one or more of its obligations under this Agreement, the University may deliver a written
notice of default to the Licensee. Without further action by a party, this Agreement shall terminate if (a) the University has
not been paid the full amount of the Administrative Handling Fee set forth in section 11 of the EPLA, and (b) the default has not
been cured in full within either sixty (60) days after the delivery to the Licensee of the notice of default if the default relates
to a payment or reimbursement obligation under this Agreement, or ninety (90) days after the delivery to the Licensee of the notice
of default if the default relates to any other matter.


 


8.1.2           The
University may terminate this Agreement by delivering to the Licensee a written notice of termination at least ten (10) days before
the date of termination if the Licensee (i) voluntarily files or has filed against it a petition under applicable bankruptcy or
insolvency laws that the Licensee fails to have released within sixty (60) days after filing; (ii) proposes any dissolution, or
if a receiver, trustee, custodian, or similar agent is appointed; or (iii) makes a general assignment for the benefit of creditors.


 


8.1.3           The
University may terminate this Agreement immediately by delivering to the Licensee a written notice of termination if the Licensee
or its agents or representatives commences or maintains an action in any court of competent jurisdiction or a proceeding before
any governmental agency asserting or alleging, in any respect, the invalidity or unenforceability of any of the Licensed Technology.


 




    	A-11



    	 



    

 


INFORMATION MARKED BY [***] HAS BEEN
OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED PORTION HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND
EXCHANGE COMMISSION.




 


8.2           By
the Licensee.


 


8.2.1           If
the University breaches or fails to perform one or more of its duties under this Agreement, the Licensee may deliver to the University
a written notice of default. The Licensee may terminate this Agreement by delivering to the University a written notice of termination
if the default has not cured in full within ninety (90) days of the delivery to the University of the notice of default.


 


8.2.2           Licensee
may, subject to the payment to the University of the Termination Fee, terminate this Agreement at any time upon written notice
of termination given to the University at least ninety (90) days prior to the date of such termination and upon the payment of
all amounts due to the University through the effective date of termination.


 


8.3           Post-termination
Period. The Licensee shall not use, or permit others to use, the Licensed Technology or manufacture or have manufactured Licensed
Products after this Agreement terminates. If the Licensee terminates this Agreement under section 8.2, the Licensee may continue
to offer to sell and sell, offer to lease and lease, and otherwise offer to dispose of or dispose of Licensed Products in the Territory
that were manufactured before such termination. The Commercial Sales of Licensed Products during the Post-termination Period shall
be governed by the terms of this Agreement, including the obligation to pay royalties on such Commercial Sales as provided in this
Agreement. If the University terminates this Agreement under section 8.1, after the date of termination, the Licensee shall not
offer to sell or sell, offer to lease or lease, or otherwise offer to dispose of or dispose of a Licensed Product in the Territory.


 


9.           Indemnification,
and Insurance.


 


9.1           The
Licensee’s Indemnification. Throughout the Term and thereafter, the Licensee shall indemnify, defend, and hold the University
and its regents, employees, and agents harmless from all suits, actions, claims, liabilities, demands, damages, losses, or expenses
(including reasonable attorneys’ and investigative expenses), relating to or arising out of the Licensee’s exercises
or attempt to exercise any of the rights or licenses granted it under this Agreement, including without limitation, the manufacture,
use, lease, sale, or other disposition of a Licensed Product or the Licensee’s breach of any term of this Agreement.


 


9.2           The
University’s Indemnification. Subject to the limitations on liability set forth in section 11, throughout the Term and thereafter,
the University shall indemnify, defend, and hold the Licensee and its directors, employees, and agents harmless from all suits,
actions, claims, liabilities, demands, damages, losses, or expenses (including reasonable attorneys’ and investigative expenses)
relating to or arising out of the University’s breach of any term of this Agreement.


 




    	A-12



    	 



    

  


 


INFORMATION MARKED BY [***] HAS BEEN
OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED PORTION HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND
EXCHANGE COMMISSION.






 


9.3           The
Licensee’s Insurance.


 


9.3.1      Throughout
the Term, or during such other period as the parties agree in writing, the Licensee shall maintain, and shall cause each Sublicensee
to maintain, in full force and effect comprehensive general liability (“CGL”) insurance, with single claim limits acceptable
to the University. Such insurance policy shall include coverage for claims that may be asserted by the University against the Licensee
under section 9.1 and for claims by a Third Party against the Licensee or the University arising out of the purchase or use of
a Licensed Product. Such insurance policy must (i) name the University as an additional insured if the University so requests in
writing and (ii) require the insurer to deliver written notice to the University at the address set forth in section 12.13, at
least thirty (30) days before the termination of the policy. Upon receipt of the University’s written request, the Licensee
shall deliver to the University a copy of the certificate of insurance for such policy.


 


9.3.2      The
provisions of subsection 9.3.1 do not apply if the University agrees in writing to accept the Licensee’s or a Sublicensee’s,
as the case may be, self-insurance plan as adequate insurance.


 


9.4           Sublicensees.
The Licensee shall cause each Sublicensee to indemnify the University to the substantially the same extent as the indemnity provided
by Licensee in favor of the University in section 9.1.


 


10.         Warranties.


 


10.1         Authority.
Each party represents and warrants to the other party that it has full corporate power and authority to execute, deliver, and perform
this Agreement, and that no other corporate proceedings by such party are necessary to authorize the party’s execution or
delivery of this Agreement.


 


10.2         University
Representations. The University represents and warrants to Licensee that, to the knowledge of either (i) the University’s
Office for Technology Commercialization or (ii) with respect to Section 10.2.3 only, the Inventors, as of the Effective Date:


 


10.2.1    there
are no outstanding agreements, assignments or encumbrances in existence inconsistent with the provisions of this Agreement;


 




    	A-13



    	 



    

 


INFORMATION MARKED BY [***] HAS BEEN
OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED PORTION HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND
EXCHANGE COMMISSION.




 


10.2.2    the
University owns or possesses all right, title and interest in and to the Licensed Patents and Licensed Patent Applications, including
all inventions claimed therein;


 


10.2.3    it
has received no written notice of claims, pending or threatened, of infringement, interference or invalidity regarding, any part
or all of the Licensed Technology; and


 


10.2.4    all
of the inventors named in the Licensed Patent Applications who are University employees have assigned, or are under an obligation
to assign, to the University of their right, title and interest in the inventions claimed therein.


 


10.3         Disclaimers.


 


10.3.1    EXCEPT
FOR THE EXPRESS WARRANTY SET FORTH ABOVE IN SECTION 10.1 AND 10.2, THE UNIVERSITY DISCLAIMS AND EXCLUDES ALL WARRANTIES,
EXPRESS AND IMPLIED, CONCERNING THE LICENSED TECHNOLOGY, EACH LICENSED PATENT, EACH LICENSED PATENT APPLICATION, AND EACH LICENSED
PRODUCT, INCLUDING, WITHOUT LIMITATION, WARRANTIES OF NON-INFRINGEMENT, OF MERCHANTABILITY AND OF FITNESS FOR A PARTICULAR PURPOSE.


 


10.3.2    The
University expressly disclaims any warranties concerning and makes no representations:


 


		(i)	that the Licensed Patent Applications will be allowed
or granted or that a patent will issue from any Licensed Patent Application;



		(ii)	concerning the validity, enforceability, interpretation
of claims or scope of any Licensed Patent; or



		(iii)	that the exercise of the rights or licenses granted to
the Licensee under this Agreement will not infringe a Third Party’s patent or violate its intellectual property rights.



 


10.4         Sublicensees
- Warranties. The Licensee shall cause each Sublicensee to give the University warranties and disclaimers and exclusions of warranties
substantially similar to the warranty and disclaimers and exclusions of warranties in favor of the University in section 10.1 and
subsections 10.2.1 and 10.2.2.


 




    	A-14



    	 



    

 


INFORMATION MARKED BY [***] HAS BEEN
OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED PORTION HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND
EXCHANGE COMMISSION.




 


11.         Damages.


 


11.1         Remedy
Limitation. EVEN IF ADVISED OF THE POSSIBILITY OF SUCH DAMAGES, THE UNIVERSITY SHALL NOT BE LIABLE FOR (A) PERSONAL INJURY
OR PROPERTY DAMAGES (EXCEPT TO THE EXTENT OF THE UNIVERSITY’S WILLFUL, WANTON, OR INTENTIONAL ACTS) OR (B) LOST PROFITS,
LOST BUSINESS OPPORTUNITY, INVENTORY LOSS, WORK STOPPAGE, LOST DATA OR ANY OTHER RELIANCE OR EXPECTANCY, DIRECT OR INDIRECT, SPECIAL,
INCIDENTAL OR CONSEQUENTIAL DAMAGES, OF ANY KIND.


 


11.2         Damage
Cap. THE UNIVERSITY’S TOTAL LIABILITY FOR THE BREACH OR NONPERFORMANCE OF THIS AGREEMENT SHALL NOT EXCEED THE AMOUNT OF
PAYMENTS PAID TO THE UNIVERSITY UNDER THIS AGREEMENT. THIS LIMITATION APPLIES TO CONTRACT, TORT, AND ANY OTHER CLAIM OF WHATEVER
NATURE.


 


11.3         Sublicensees
- Damages. The Licensee shall cause each Sublicensee to agree to limitations of remedies and damages substantially similar to the
limitations of remedies and damages set forth in sections 11.1 and 11.2.


 


12.         General
Terms


 


12.1         Access
to University Information.


 


12.1.1    Data
Practices Act. The parties acknowledge that the University is subject to the terms and provisions of the Minnesota Government Data
Practices Act, Minnesota Statutes §13.01 et seq. (the “Act”), and that the Act requires, with certain exceptions,
the University to permit the public to inspect and copy any information that the University collects, creates, receives, maintains,
or disseminates.


 


12.1.2    Confidentiality.
To the extent permitted by law, including as provided in the Act, the University shall hold in confidence and disclose only to
University employees, agents and contractors who need to know the reports described in sections 5.4 and 6.4 and the records inspected
in accordance with section 6.5 of the Terms and Conditions. No provision of this Agreement is to be construed to further prohibit,
limit, or condition the University’s right to use and disclose any information in connection with enforcing this Agreement,
in court or elsewhere.


 


12.2         Amendment
and Waiver. The Agreement may be amended from time to time only by a written instrument signed by the parties. No term or
provision of this Agreement may be waived and no breach excused unless such waiver or consent is in writing and signed by the party
claimed to have waived or consented. No waiver of a breach is to be deemed a waiver of a different or subsequent breach.


 




    	A-15



    	 



    

 


INFORMATION MARKED BY [***] HAS BEEN
OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED PORTION HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND
EXCHANGE COMMISSION.




 


12.3         Applicable
Law and Forum Selection. The internal laws of the state of Minnesota, without giving effect to its conflict of laws principles,
govern the validity, construction, and enforceability of this Agreement. A suit, claim, or other action to enforce the terms of
this Agreement may be brought only in the state or federal courts situated in or having jurisdiction over Hennepin County, Minnesota.
The Licensee hereby submits to the jurisdiction of that court and waives any objections it may have to that court asserting jurisdiction
over the Licensee or its assets and property.


 


12.4         Assignment
and Sublicense. Except as permitted under subsection 3.1.2 and section 12.5 of the Terms and Conditions, the Licensee shall not
assign or sublicense its interest or delegate its duties under this Agreement. Any assignment, sublicense, or delegation attempted
to be made in violation of this section is void. Absent the consent of all the parties, an assignment or delegation will not release
the assigning or delegating party from its obligations. The Agreement inures to the benefit of the Licensee and the University
and their respective permitted Sublicensees and trustees.


 


12.5         Change
of Control. Notwithstanding section 12.4, the Licensee, without the prior approval of the University, may assign all, but
no less than all, its rights and delegate all its duties under this Agreement to another if (i) the Licensee delivers to the University
written notice of the proposed assignment (along with pertinent information about the terms of the assignment and assignee) at
least sixty (60) days before the effective date of the event described in clause (iii) of this paragraph, (ii) to the extent payable
in accordance with Section 11.8 of the EPLA, pay to the University the Transfer Payment prior to the effective date of the event
described in part iii of this paragraph, and (iii) the assignment is made as a part of and in connection with (a) the sale by the
Licensee of all or substantially all of its assets to a single purchaser (or group of affiliated purchasers), (b) the sale, transfer,
or exchange by the shareholders or equity owners of the Licensee of a majority interest in the Licensee to a single purchaser (or
group of affiliated purchasers), or (c) the merger of the Licensee into another corporation or other business entity. Any assignment
attempted to be made or made in violation of this subsection is void.


 


12.6         Collection
Costs and Attorneys’ Fees. If a party fails to perform an obligation or otherwise breaches one or more of the terms of this
Agreement, the other party may recover from the non-performing breaching party all its reasonable costs (including actual attorneys’
and investigative fees) to enforce the terms of this Agreement.


 


12.7         Consent
and Approvals. Except as otherwise expressly provided, in order to be effective, all consents or approvals required under this
Agreement must be in writing.


 




    	A-16



    	 



    

 


INFORMATION MARKED BY [***] HAS BEEN
OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED PORTION HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND
EXCHANGE COMMISSION.




 


12.8        Construction.
The headings preceding and labeling the sections of this Agreement are for the purpose of identification only and are not to be
employed or used for the purpose of construction or interpretation of any portion of the EPLA. As used herein and where necessary,
the singular includes the plural and vice versa, and masculine, feminine, and neuter expressions are interchangeable.


 


12.9        Enforceability.
If a court of competent jurisdiction adjudges a provision of this Agreement to be unenforceable, invalid, or void, such determination
is not to be construed as impairing the enforceability of any of the remaining provisions hereof and such provisions will remain
in full force and effect.


 


12.10      Entire
Agreement. The parties intend this Agreement (including all attachments, exhibits, and amendments hereto) to be the final and binding
expression of their contract and agreement and the complete and exclusive statement of the terms thereof. The Agreement cancels,
supersedes, and revokes all prior negotiations, representations and agreements among the parties, whether oral or written, relating
to the subject matter of this Agreement.


 


12.11      Language
and Currency. Unless otherwise expressly provided in this Agreement and in order to be effective, all notices, reports, and other
documents and instruments that a party elects or is required to deliver to the other party must be in English, and all notices,
reports, and other documents and instruments detailing revenues and earned under this Agreement or expenses chargeable to a party
must be United States dollar denominated.


 


12.12      No
Third-Party Beneficiaries. No provision of this Agreement, express or implied, is intended to confer upon any person other than
the parties to this Agreement any rights, remedies, obligations, or liabilities hereunder. No Sublicensee may enforce or seek damages
under this Agreement.


 


12.13      Notices.
In order to be effective, all notices, requests, and other communications that a party is required or elects to deliver must be
in writing and must be delivered personally, or by facsimile or electronic mail (provided such delivery is confirmed), or by a
recognized overnight courier service or by United States mail, first-class, certified or registered, postage prepaid, return receipt
requested, to the other party at its address set forth below or to such other address as such party may designate by notice given
under this section:


 


	If to the University:	University of Minnesota 
	 	Office for Technology Commercialization
	 	200 Oak Street, SE, Suite 280
	 	Minneapolis, MN 55445
	 	Phone: 612.624.0550 
	 	Fax: 612.624.6554 


 




    	A-17



    	 



    

 


INFORMATION MARKED BY [***] HAS BEEN
OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED PORTION HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND
EXCHANGE COMMISSION.




 


	 	E-mail: otcagree@umn.edu  
	 	 
	For notices sent	University of Minnesota
	under section 8,	Office of the General Counsel
	with a copy to:	Attn: Transactional Law Services
	 	360 McNamara Alumni Center
	 	200 Oak Street S.E.
	 	Minneapolis, MN 55455-2006
	 	Facsimile No.: 612.626.9624
	 	E-mail: contracts@mail.ogc.umn.edu
	 	 
	If to the Licensee:	As indicated in section 12 of the EPLA.


 


12.14      Relationship
of Parties. In entering into, and performing their duties under this Agreement, the parties are acting as independent contractors
and independent employers. No provision of this Agreement creates or is to be construed as creating a partnership, joint venture,
or agency relationship between the parties. No party has the authority to act for or bind the other party in any respect.


 


12.15      Security
Interest. In no event may the Licensee grant, or permit any person to assert or perfect, a security interest in the Licensee’s
rights under this Agreement.


 


12.16      Survival.
Immediately upon the termination or expiration of this Agreement, except for certain rights granted for the Post-termination Period,
all the Licensee’s rights under this Agreement terminate; provided, however, the Licensee’s obligations that have accrued
before the effective date of termination or expiration (e.g., the obligation to report and make payments on sales, leases,
or dispositions of Licensed Products and to reimburse the University for costs) and the obligations specified in section 6.1 survive.
The obligations and rights set forth in sections 6.4 and 8.3 and sections 9, 10, and 11 also survive the termination or expiration
of this Agreement.


 




    	A-18